International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology

Solez, Kim; Axelsen, Roy A.; Benediktsson, Hallgrimur; Burdick, James F.; Cohen, Arthur H.; Colvin, Robert B.; Croker, Byron P.; Droz, Dominique; Dunnill, Michael S.; Halloran, Philip F.; Häyry, Pekka; Jennette, J. Charles; Keown, Paul A.; Marcussen, Niels; Mihatsch, Michael J.; Morozumi, Kunio; Myers, Bryan D.; Nast, Cynthia C.; Olsen, Steen; Racusen, Lorraine C.
August 1993
Kidney International;Aug1993, Vol. 44 Issue 2, p411
Academic Journal
A group of renal pathologists, nephrologists, and transplant surgeons met in Banff, Canada on August 2–4, 1991 to develop a schema for international standardization of nomenclature and criteria for the histologic diagnosis of renal allograft rejection. Development continued after the meeting and the schema was validated by the circulation of sets of slides for scoring by participant pathologists. In this schema intimal arteritis and tubulitis are the principal lesions indicative of acute rejection. Glomerular, interstitial, tubular, and vascular lesions of acute rejection and ‘chronic rejection’ are defined and scored 0 to 3+, to produce an acute and/or chronic numerical coding for each biopsy. Arteriolar hyalinosis (an indication of cyclosporine toxicity) is also scored. Principal diagnostic categories, which can be used with or without the quantitative coding, are; (1) normal, (2) hyperacute rejection, (3) borderline changes, (4) acute rejection (grade I to III), (5) chronic allograft nephropathy (‘chronic rejection’) (grade I to III), and (6) other. The goal is to devise a schema in which a given biopsy grading would imply a prognosis for a therapeutic response or long-term function. While the clinical implications must be proven through further studies, the development of a standardized schema is a critical first step. This standardized classification should promote international uniformity in reporting of renal allograft pathology, facilitate the performance of multicenter trials of new therapies in renal transplantation, and ultimately lead to improvement in the management and care of renal transplant recipients.


Related Articles

  • Cytomegalovirus and Leishmania donovani coinfection in a renal allograft recipient. Prasad, N.; Gupta, A.; Sharma, R. K.; Gopalakrishnan, S.; Agrawal, V.; Jain, M. // Indian Journal of Nephrology;Apr-Jun2011, Vol. 21 Issue 2, p128 

    Infection is a leading cause of death in renal allograft recipients. Apart from the immunosuppressive drugs, immunomodulatory viral infections also predispose the recipient to many opportunistic infections. Kala-azar in renal allograft recipients is infrequently reported even in endemic areas....

  • Combating Chronic Renal Allograft Dysfunction: Optimal Immunosuppressive Regimens. Merville, Pierre // Drugs;2005, Vol. 65 Issue 5, p615 

    Kidney transplantation is the best treatment for patients with end-stage renal disease, both in terms of survival benefit and quality of life. The major limitation is the continuing shortage of kidneys suitable for transplantation, reinforcing the need to maximise graft survival. After the first...

  • Risk of Renal Allograft Loss from Recurrent Glomerulonephritis. Briganti, Esther M.; Russ, Graeme R.; McNeil, John J.; Atkins, Robert C.; Chadban, Steven J. // New England Journal of Medicine;7/11/2002, Vol. 347 Issue 2, p103 

    Background: Recurrent glomerulonephritis is a known cause of renal allograft loss; however, the incidence of this complication is poorly defined. We determined the incidence, timing, and relative importance of allograft loss due to the recurrence of glomerulonephritis. Methods: A total of 1505...

  • EPIDEMIOLOGY OF PRA IN PRE TRANSPLANT RENAL RECIPIENTS AND ITS RELATION TO DIFFERENT FACTORS. Mohamady, Usama; Abdelrahman, Ihab; Soliman, Karim Magdy; Belal, Dawlat Abdelhamid; Elansary, Mervat // International Journal of Academic Research;Jan2014, Vol. 6 Issue 1, p127 

    Previous data indicated that PRA responses in the pre-transplantation and the early post-transplantation periods correlate with kidney allograft rejection and that differences in PRA levels are associated with significant differences in graft rejection (7).

  • A clinical scoring system highly predictive of long-term kidney graft survival. Foucher, Yohann; Daguin, Pascal; Akl, Ahmed; Kessler, Michèle; Ladrière, Marc; Legendre, Christophe; Kreis, Henri; Rostaing, Lionel; Kamar, Nassim; Mourad, Georges; Garrigue, Valérie; Bayle, François; de Ligny, Bruno H.; B9#x00FC;chler, Mathias; Meier, Carole; Daurès, Jean P.; Soulillou, Jean-Paul; Giral, Magali // Kidney International;Dec2010, Vol. 78 Issue 12, p1288 

    Determining early surrogate markers of long-term graft outcome is important for optimal medical management. In order to identify such markers, we used clinical information from a cross-validated French database (Données Informatisées et VAlidées en Transplantation) of 2169 kidney...

  • Renal Cell Carcinoma in a Renal Allograft Successful Treatment with 5 Year Follow-up. Thomalla, J. Vincent // Clinical Medicine & Research;Aug2004, Vol. 2 Issue 3, p151 

    Renal cell carcinoma (RCC) developing in a renal allograft either as a result of undetected presence within the donor organ or as a consequence of de novo development post transplantation is a rare event. The Cincinnati Transplant Tumor Registry has recorded 45 cases of RCC developing in a renal...

  • Renal medullary changes in renal allograft recipients with raised serum creatinine. Sis, B.; Sarioglu, S.; Celik, A.; Kasap, B.; Yildiz, S.; Kavukcu, S.; Gulay, H.; Camsari, T. // Journal of Clinical Pathology;Apr2006, Vol. 59 Issue 4, p377 

    Objective: To test the hypothesis that the renal medulla may reflect rejection related changes and thus have a predictive value in the assessment of acute renal allograft rejection or chronic graft damage. Methods: 75 post-transplant biopsies from 57 patients were scored according to the Banff...

  • High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection? Wolfgang Altermann; Gerald Schlaf; Anita Rothhoff; Barbara Seliger // Nephrology Dialysis Transplantation;Oct2007, Vol. 22 Issue 10, p2795 

    Background. Previous studies have suggested that the pre-transplant levels of the soluble CD30 molecule (sCD30) represent a non-invasive tool which can be used as a biomarker for the prediction of kidney allograft rejections. Methods. In order to evaluate the feasibility of sCD30 for...

  • Mercaptoacetyltriglycine diuretic renography and output efficiency measurement in renal transplant patients. Spicer, S. Timothy; Chi, Ka-Kit; Nankivell, Brian J.; Larcos, George; Farlow, David C.; Choong, Kevin K. L.; Chapman, Jeremy R.; Gruenewald, Simon M. // European Journal of Nuclear Medicine;1999, Vol. 26 Issue 2, p152 

    Abstract Suspected urinary tract obstruction following renal transplantation presents a diagnostic dilemma. The purposes of this study were: (1) to establish a normal range of measurement of output efficiency (OE) in the renal transplant population, and (2) to assess prospectively the usefulness...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics